Evotec Shares Plunge to Fresh Annual Low Amid Operational Struggles

Evotec shares hit a 52-week low, halving from last year's peak. The decline is driven by falling revenue, widening losses, and a challenging macroeconomic environment for biotech stocks.

The persistent operational weakness at Evotec is taking a significant toll on its market valuation. The drug discovery specialist's stock has now fallen to its lowest point in a year, reflecting broader pressures on the biotech sector and growing investor unease over the company's prolonged lack of profitability.

A Halving of Shareholder Value

The stock's dramatic decline is starkly illustrated in its recent trading activity. On Friday, shares touched a new 52-week low of €4.14. This price represents a precise 50% collapse from the high of €8.32 reached in May of last year. The current trading level sits approximately 30% below its 50-day moving average, highlighting the intense downward momentum that has built over recent weeks. For any meaningful technical recovery to take hold, the company's management must demonstrate a clear stabilization of its operating margins and a convincing return to revenue growth in upcoming quarterly reports.

Deteriorating Fundamentals and a Challenging Market

The primary driver behind this negative price action is a bleak business outlook. Recent quarterly figures already revealed a drop in revenue to just under €164 million and a widening net loss. The fundamental picture offers little support, with analysts forecasting a full-year 2025 loss per share of €0.46.

Compounding these company-specific issues is a difficult macroeconomic backdrop. Unexpectedly high inflation data from the United States has reignited fears of stagflation, pushing major U.S. technology indices into negative territory. This development is sapping liquidity from the market and placing additional pressure on growth-oriented mid-cap stocks within the TecDAX, affecting companies across sectors including biotechnology.